Adhikari Raju, Gunatillake Pathiraja A, Griffiths Ian, Tatai Lisa, Wickramaratna Malsha, Houshyar Shadi, Moore Tim, Mayadunne Roshan T M, Field John, McGee Margaret, Carbone Tania
PolyNovo Biomaterials Limited, Bayview Avenue, Clayton South 3169, Victoria, Australia.
Biomaterials. 2008 Oct;29(28):3762-70. doi: 10.1016/j.biomaterials.2008.06.021. Epub 2008 Jul 15.
Biodegradable polyurethanes offer advantages in the design of injectable or preformed scaffolds for tissue engineering and other medical implant applications. We have developed two-part injectable prepolymer systems (prepolymer A and B) consisting of lactic acid and glycolic acid based polyester star polyols, pentaerythritol (PE) and ethyl lysine diisocyanate (ELDI). This study reports on the formulation and properties of a series of cross linked polyurethanes specifically developed for orthopaedic applications. Prepolymer A was based on PE and ELDI. Polyester polyols (prepolymer B) were based on PE and dl-lactic acid (PEDLLA) or PE and glycolic acid (PEGA) with molecular weights 456 and 453, respectively. Several cross linked porous and non-porous polyurethanes were prepared by mixing and curing prepolymers A and B and their mechanical and thermal properties, in vitro (PBS/37 degrees C/pH 7.4) and in vivo (sheep bi-lateral) degradation evaluated. The effect of incorporating beta-tricalcium phosphate (beta-TCP, 5 microns, 10 wt.%) was also investigated. The cured polymers exhibited high compressive strength (100-190 MPa) and modulus (1600-2300 MPa). beta-TCP improved mechanical properties in PEDLLA based polyurethanes and retarded the onset of in vitro and in vivo degradation. Sheep study results demonstrated that the polymers in both injectable and precured forms did not cause any surgical difficulties or any adverse tissue response. Evidence of new bone growth and the gradual degradation of the polymers were observed with increased implant time up to 6 months.
可生物降解的聚氨酯在用于组织工程和其他医学植入应用的可注射或预制支架设计中具有优势。我们开发了由基于乳酸和乙醇酸的聚酯星形多元醇、季戊四醇(PE)和赖氨酸二异氰酸乙酯(ELDI)组成的双组分可注射预聚物体系(预聚物A和B)。本研究报告了一系列专门为骨科应用开发的交联聚氨酯的配方和性能。预聚物A基于PE和ELDI。聚酯多元醇(预聚物B)基于PE和dl-乳酸(PEDLLA)或PE和乙醇酸(PEGA),分子量分别为456和453。通过混合和固化预聚物A和B制备了几种交联的多孔和无孔聚氨酯,并对其力学和热性能、体外(PBS/37℃/pH 7.4)和体内(绵羊双侧)降解情况进行了评估。还研究了加入β-磷酸三钙(β-TCP,5微米,10重量%)的效果。固化后的聚合物表现出高抗压强度(100-190 MPa)和模量(1600-2300 MPa)。β-TCP改善了基于PEDLLA的聚氨酯的力学性能,并延缓了体外和体内降解的开始。绵羊研究结果表明,可注射和预固化形式的聚合物均未引起任何手术困难或任何不良组织反应。随着植入时间延长至6个月,观察到了新骨生长和聚合物逐渐降解的迹象。